Angiogenesis in Gynecological Cancers: Role of Neurotrophins
review
OA: gold
CC0
⤵ 3 in-corpus citations
Abstract
Angiogenesis, or generation of new blood vessels from other pre-existing, is a key process to maintain the supply of nutrients and oxygen in tissues. Unfortunately, this process is exacerbated in pathologies such as retinopathies and cancers with high angiogenesis as ovarian cancer. Angiogenesis is regulated by multiple systems including growth factors and neurotrophins. One of the most studied angiogenic growth factors is the vascular endothelial growth factor (VEGF), which is overexpressed in several cancers. It has been recently described that neurotrophins could regulate angiogenesis through direct and indirect mechanisms. Neurotrophins are a family of proteins that include nerve growth factor (NGF), brain-derived growth factor (BDNF), and neurotrophins 3 and 4/5 (NT 3, NT 4/5). These molecules and their high affinity receptors (TRKs) regulate the development, maintenance, and plasticity of the nervous system. Furthermore, it was recently described that they display essential functions in non-neuronal tissues, such as reproductive organs among others. Studies have shown that several types of cancer overexpress neurotrophins such as NGF and BDNF, which might contribute to tumor progression and angiogenesis. Besides, in recent years the FDA has approved the use of pharmacologic inhibitors of pan-TRK receptors in patients with TRKs fusion-positive cancers. In this review, we discuss the mechanisms by which neurotrophins stimulate tumor progression and angiogenesis, with emphasis on gynecological cancers.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (100)
- Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells via openalex
- Endometriosis as a risk factor for ovarian or endometrial cancer — results of a hospital-based case–control study via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Expression of nerve growth factor and its receptors in the uterus of rabbits: functional involvement in prostaglandin synthesis via openalex
- Increased Association Between Endometriosis and Endometrial Cancer via openalex
- Is Endometriosis a Preneoplastic Condition? via openalex
- Localization of TrkB and p75 receptors in peritoneal and deep infiltrating endometriosis: an immunohistochemical study via openalex
- Nerve Growth Factor Induces Vascular Endothelial Growth Factor Expression in Granulosa Cells via a trkA Receptor/Mitogen-Activated Protein Kinase-Extracellularly Regulated Kinase 2-Dependent Pathway via openalex
- Proteomic identification of neurotrophins in the eutopic endometrium of women with endometriosis via openalex
- Retracted Article: Ginsenoside Rf alleviates dysmenorrhea and inflammation through the BDNF-TrkB-CREB pathway in a rat model of endometriosis via openalex
- Vascular endothelial growth factor and endometriotic angiogenesis via openalex
- W1687956552 via openalex
- W1954362343 via openalex
- W1965880842 via openalex
- W1971340644 via openalex
- W1972747845 via openalex
- W1973994766 via openalex
- W1975111610 via openalex
- W1983141048 via openalex
- W1988509493 via openalex
- W1993235364 via openalex
- W1996606153 via openalex
- W2000757618 via openalex
- W2004303128 via openalex
- W2007531722 via openalex
- W2008398839 via openalex
- W2010892208 via openalex
- W2010947174 via openalex
- W2012055715 via openalex
- W2014087704 via openalex
- W2014282546 via openalex
- W2015186671 via openalex
- W2015344488 via openalex
- W2015670731 via openalex
- W2018615370 via openalex
- W2019288143 via openalex
- W2020990588 via openalex
- W2021824954 via openalex
- W2024290930 via openalex
- W2025036947 via openalex
- W2026639628 via openalex
- W2030204732 via openalex
- W2039625166 via openalex
- W2039914719 via openalex
- W2044500507 via openalex
- W2047863140 via openalex
- W2047951596 via openalex
- W2058384954 via openalex
- W2059452299 via openalex
- W2065767769 via openalex
- W2065903778 via openalex
- W2066560125 via openalex
- W2068176952 via openalex
- W2071389244 via openalex
- W2078056350 via openalex
- W2080785485 via openalex
- W2093089884 via openalex
- W2094858086 via openalex
- W2098533150 via openalex
- W2099258232 via openalex
- W2101179492 via openalex
- W2102297721 via openalex
- W2102813174 via openalex
- W2103276585 via openalex
- W2104105395 via openalex
- W2105147680 via openalex
- W2106578431 via openalex
- W2106787323 via openalex
- W2110802986 via openalex
- W2112911107 via openalex
- W2115028867 via openalex
- W2115423015 via openalex
- W2120156974 via openalex
- W2120219709 via openalex
- W2120421707 via openalex
- W2121867072 via openalex
- W2124765869 via openalex
- W2126605121 via openalex
- W2127442706 via openalex
- W2131545168 via openalex
- W2134222140 via openalex
- W2135251891 via openalex
- W2135887304 via openalex
- W2137564768 via openalex
- W2138783075 via openalex
- W2142566812 via openalex
- W2149158668 via openalex
- W2149182374 via openalex
- W2153003431 via openalex
- W2157634837 via openalex
- W2165690835 via openalex
- W2171814302 via openalex
- W2172410248 via openalex
- W2211298198 via openalex
- W2308355939 via openalex
- W2329129125 via openalex
- W2338990099 via openalex
- W2397795508 via openalex
- W2411330078 via openalex
- W2416050061 via openalex
Cited by (3)
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK